What is the creatinine clearance threshold at which Truvada should not be administered?

The threshold for creatinine clearance at which Truvada should not be administered is indeed significant for patient safety, especially concerning the drug's impact on kidney function. Truvada, used in HIV treatment and for pre-exposure prophylaxis (PrEP), can lead to renal toxicity, and careful monitoring of kidney function is essential.

When creatinine clearance falls below 30 ml/min, the risk of cumulative drug toxicity increases substantially. Below this level, the kidneys are not effectively clearing the medication from the system, leading to higher potential drug levels in the body, which can exacerbate side effects or lead to acute kidney injury.

The other thresholds provided (60 ml/min, 45 ml/min, and 15 ml/min) do not align with the established guidelines. A clearance rate of 60 ml/min and above is generally considered safe for Truvada, as it indicates that the kidneys are functioning adequately to process the drug. While a 45 ml/min clearance might raise concerns and necessitate closer monitoring, it does not represent the definitive threshold below which Truvada should be discontinued. A clearance value of 15 ml/min indicates severe renal impairment, but it is already understood that Truvada should not be used at the higher threshold of